Search results
Results from the WOW.Com Content Network
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid ( lenalidomide ), which is used in the treatment of multiple myeloma , and also in certain anemias.
(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for the cancer drug Breyanzi and ...
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a ...
Celgene Prices $1.5 Billion of Senior Unsecured Notes SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (Nasdaq: CELG) today announced the successful pricing of three series of senior unsecured ...
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q2 results.
Celgene Corporation Announces Financial Outlook and Preliminary 2012 Results 2012 Adjusted Diluted EPS Expected to be at the Higher End of Previous Guidance Range at Approximately $4.90 (GAAP ...
Celgene Corporation [22] [23] $280,000,000 $280 million (civil only; non-intervened) Off-label promotion/ kickbacks/Medicare fraud False Claims Act/FDCA 2003 18 17 Zoladex: AstraZeneca [24] $355,000,000 $266 million ($355 million with criminal component) Medicare fraud Prescription Drug Marketing Act 2006 15 18 Temodar/ Intron A/K-Dur/ Claritin ...
The total settlement remained the largest against a pharmaceutical company in a non-intervened False Claims Act case until a July 2017 settlement against Celgene Corporation exceeded it, as the civil settlement in that case was $280 million while the civil component of the Parke-Davis case settled for $190 million. [3] [circular reference]